BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 32768701)

  • 1. Low-dose subcutaneous tocilizumab to prevent disease progression in patients with moderate COVID-19 pneumonia and hyperinflammation.
    Potere N; Di Nisio M; Rizzo G; La Vella M; Polilli E; Agostinone A; Spacone A; Di Carlo S; Costantini A; Abbate A; Porreca E; Parruti G
    Int J Infect Dis; 2020 Nov; 100():421-424. PubMed ID: 32768701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Appropriate use of tocilizumab in COVID-19 infection.
    Keske Ş; Tekin S; Sait B; İrkören P; Kapmaz M; Çimen C; Uğur S; Çelebi İ; Bakır VO; Palaoğlu E; Şentürk E; Çağlayan B; Çakar N; Tabak L; Ergönül Ö
    Int J Infect Dis; 2020 Oct; 99():338-343. PubMed ID: 32726724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tocilizumab treatment in COVID-19: A single center experience.
    Luo P; Liu Y; Qiu L; Liu X; Liu D; Li J
    J Med Virol; 2020 Jul; 92(7):814-818. PubMed ID: 32253759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis.
    Rossotti R; Travi G; Ughi N; Corradin M; Baiguera C; Fumagalli R; Bottiroli M; Mondino M; Merli M; Bellone A; Basile A; Ruggeri R; Colombo F; Moreno M; Pastori S; Perno CF; Tarsia P; Epis OM; Puoti M;
    J Infect; 2020 Oct; 81(4):e11-e17. PubMed ID: 32652164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy.
    Toniati P; Piva S; Cattalini M; Garrafa E; Regola F; Castelli F; Franceschini F; Airò P; Bazzani C; Beindorf EA; Berlendis M; Bezzi M; Bossini N; Castellano M; Cattaneo S; Cavazzana I; Contessi GB; Crippa M; Delbarba A; De Peri E; Faletti A; Filippini M; Filippini M; Frassi M; Gaggiotti M; Gorla R; Lanspa M; Lorenzotti S; Marino R; Maroldi R; Metra M; Matteelli A; Modina D; Moioli G; Montani G; Muiesan ML; Odolini S; Peli E; Pesenti S; Pezzoli MC; Pirola I; Pozzi A; Proto A; Rasulo FA; Renisi G; Ricci C; Rizzoni D; Romanelli G; Rossi M; Salvetti M; Scolari F; Signorini L; Taglietti M; Tomasoni G; Tomasoni LR; Turla F; Valsecchi A; Zani D; Zuccalà F; Zunica F; Focà E; Andreoli L; Latronico N
    Autoimmun Rev; 2020 Jul; 19(7):102568. PubMed ID: 32376398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study.
    Moreno-Pérez O; Andres M; Leon-Ramirez JM; Sánchez-Payá J; Rodríguez JC; Sánchez R; García-Sevila R; Boix V; Gil J; Merino E
    J Autoimmun; 2020 Nov; 114():102523. PubMed ID: 32690352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients.
    Klopfenstein T; Zayet S; Lohse A; Selles P; Zahra H; Kadiane-Oussou NJ; Toko L; Royer PY; Balblanc JC; Gendrin V; Conrozier T;
    Int J Infect Dis; 2020 Oct; 99():491-495. PubMed ID: 32798660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of tocilizumab in patients with COVID-19 ARDS undergoing noninvasive ventilation.
    Menzella F; Fontana M; Salvarani C; Massari M; Ruggiero P; Scelfo C; Barbieri C; Castagnetti C; Catellani C; Gibellini G; Falco F; Ghidoni G; Livrieri F; Montanari G; Casalini E; Piro R; Mancuso P; Ghidorsi L; Facciolongo N
    Crit Care; 2020 Sep; 24(1):589. PubMed ID: 32993751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial.
    Hermine O; Mariette X; Tharaux PL; Resche-Rigon M; Porcher R; Ravaud P;
    JAMA Intern Med; 2021 Jan; 181(1):32-40. PubMed ID: 33080017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarker variation in patients successfully treated with tocilizumab for severe coronavirus disease 2019 (COVID-19): results of a multidisciplinary collaboration.
    Conrozier T; Lohse A; Balblanc JC; Dussert P; Royer PY; Bossert M; Bozgan AM; Gendrin V; Charpentier A; Toko L; Badie J; Mezher C; Roux MF; Kadiane-Oussou NJ; Contreras R; Kessler J; Mazurier I; Klopfenstein T; Zayet S
    Clin Exp Rheumatol; 2020; 38(4):742-747. PubMed ID: 32573419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute Hypertriglyceridaemia Caused by Tocilizumab in a Patient with Severe COVID-19.
    Nakamura H; Miyagi K; Otsuki M; Higure Y; Nishiyama N; Kinjo T; Nakamatsu M; Haranaga S; Tateyama M; Fujita J
    Intern Med; 2020 Nov; 59(22):2945-2949. PubMed ID: 32963155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study.
    Campochiaro C; Della-Torre E; Cavalli G; De Luca G; Ripa M; Boffini N; Tomelleri A; Baldissera E; Rovere-Querini P; Ruggeri A; Monti G; De Cobelli F; Zangrillo A; Tresoldi M; Castagna A; Dagna L;
    Eur J Intern Med; 2020 Jun; 76():43-49. PubMed ID: 32482597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of tocilizumab in the treatment of severe acute respiratory syndrome coronavirus-2 pneumonia: A retrospective cohort study.
    Patel A; Shah K; Dharsandiya M; Patel K; Patel T; Patel M; Reljic T; Kumar A
    Indian J Med Microbiol; 2020; 38(1):117-123. PubMed ID: 32719218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tocilizumab and steroid treatment in patients with COVID-19 pneumonia.
    Mikulska M; Nicolini LA; Signori A; Di Biagio A; Sepulcri C; Russo C; Dettori S; Berruti M; Sormani MP; Giacobbe DR; Vena A; De Maria A; Dentone C; Taramasso L; Mirabella M; Magnasco L; Mora S; Delfino E; Toscanini F; Balletto E; Alessandrini AI; Baldi F; Briano F; Camera M; Dodi F; Ferrazin A; Labate L; Mazzarello G; Pincino R; Portunato F; Tutino S; Barisione E; Bruzzone B; Orsi A; Schenone E; Rosseti N; Sasso E; Da Rin G; Pelosi P; Beltramini S; Giacomini M; Icardi G; Gratarola A; Bassetti M
    PLoS One; 2020; 15(8):e0237831. PubMed ID: 32817707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tocilizumab for severe COVID-19 pneumonia: Case series of 5 Australian patients.
    West TA; Malik S; Nalpantidis A; Tran T; Cannon C; Bhonagiri D; Chan K; Cheong E; Wan Sai Cheong J; Cheung W; Choudhury F; Ernest D; Farah CS; Fernando S; Kanapathipillai R; Kol M; Murfin B; Naqvi H; Shah A; Wagh A; Ojaimi S; Frankum B; Riminton S; Keat K
    Int J Rheum Dis; 2020 Aug; 23(8):1030-1039. PubMed ID: 32881350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First case of drug-induced liver injury associated with the use of tocilizumab in a patient with COVID-19.
    Muhović D; Bojović J; Bulatović A; Vukčević B; Ratković M; Lazović R; Smolović B
    Liver Int; 2020 Aug; 40(8):1901-1905. PubMed ID: 32478465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab.
    Morrison AR; Johnson JM; Griebe KM; Jones MC; Stine JJ; Hencken LN; To L; Bianchini ML; Vahia AT; Swiderek J; Ramesh MS; Peters MA; Smith ZR
    J Autoimmun; 2020 Nov; 114():102512. PubMed ID: 32646770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients.
    Klopfenstein T; Zayet S; Lohse A; Balblanc JC; Badie J; Royer PY; Toko L; Mezher C; Kadiane-Oussou NJ; Bossert M; Bozgan AM; Charpentier A; Roux MF; Contreras R; Mazurier I; Dussert P; Gendrin V; Conrozier T;
    Med Mal Infect; 2020 Aug; 50(5):397-400. PubMed ID: 32387320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Hydroxychloroquine and Tocilizumab in Patients With COVID-19: Single-Center Retrospective Chart Review.
    Roomi S; Ullah W; Ahmed F; Farooq S; Sadiq U; Chohan A; Jafar M; Saddique M; Khanal S; Watson R; Boigon M
    J Med Internet Res; 2020 Sep; 22(9):e21758. PubMed ID: 32784192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study.
    Ramiro S; Mostard RLM; Magro-Checa C; van Dongen CMP; Dormans T; Buijs J; Gronenschild M; de Kruif MD; van Haren EHJ; van Kraaij T; Leers MPG; Peeters R; Wong DR; Landewé RBM
    Ann Rheum Dis; 2020 Sep; 79(9):1143-1151. PubMed ID: 32719045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.